Denial of Wyeth appeal in high court likely to affect pending HRT cases
Wyeth Pharmaceuticals has lost its appeal to the Supreme Court of Pennsylvania in 14 consolidated cases alleging that its hormone replacement therapy (HRT) drugs had caused breast cancer. Trial lawyers say the decision, which makes the discovery rule an issue of fact for the jury, will likely affect the 15,000 HRT cases pending in lower court.
